DSIP is a naturally occurring neuropeptide that promotes deep delta (slow-wave) sleep — the most restorative sleep stage — while also modulating the HPA axis stress response and reducing nighttime cortisol elevation.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide first isolated from rabbit brain in 1974 by Monnier and colleagues in Switzerland. It was identified by its ability to induce delta sleep — the slow-wave stage of sleep associated with physical restoration, growth hormone release, and memory consolidation — when infused into the brain of experimental animals. DSIP crosses the blood-brain barrier readily and acts on multiple neurological targets, with research spanning sleep induction, HPA axis modulation, pain control, antioxidant activity, and endocrine regulation.
Mechanism of Action
DSIP's mechanism is not fully characterized due to its complex multi-receptor activity. It modulates GABA neurotransmission, serotonin receptor sensitivity, and the activity of somatostatin — the hormone that suppresses growth hormone release. By reducing somatostatin activity, DSIP indirectly permits a stronger overnight GH pulse. In the hypothalamic-pituitary-adrenal (HPA) axis, DSIP reduces cortisol secretion and normalizes the dysregulated cortisol patterns (high evening cortisol, low morning cortisol) that characterize chronic stress. It also appears to act as an antioxidant by reducing reactive oxygen species and protecting mitochondria from stress-induced damage. Its sleep-promoting effects involve potentiating delta wave EEG activity without suppressing REM sleep, unlike pharmaceutical sleep aids.
Key Research
DSIP was first isolated and characterized by Monnier et al. (1977, Pflügers Archiv). Russian research groups published extensively on DSIP's clinical applications, including trials in insomnia, opiate withdrawal, and pain. Animal studies confirmed its EEG slow-wave promotion without REM suppression. HPA axis normalization was documented in stressed animal models and preliminary human research. Anti-aging and antioxidant properties were studied at the St. Petersburg Institute of Bioregulation and Gerontology. A 1984 controlled study showed DSIP significantly improved sleep quality in patients with chronic insomnia. Opiate withdrawal trials showed DSIP reduced abstinence symptoms — suggesting its HPA normalization effects extend to addiction recovery contexts.
200–300 mcg subcutaneously 30–45 minutes before bed
Half-Life
~15–30 minutes
The standard research dose is 200–300 mcg subcutaneously, administered 30–45 minutes before bed. Consistency of timing improves results — use at the same time each night. DSIP does not require a loading phase; effects are noticeable from the first dose in most subjects. Some protocols use it 5 nights per week rather than daily to prevent tolerance. Cycle: 6–8 weeks on, 2–4 weeks off. Commonly combined with Selank for pre-sleep anxiety reduction and with low-dose GHRP-6 for the overnight GH pulse component.
Sleep Optimization Stack: DSIP 200–300 mcg SC 30 min before bed + Selank 250 mcg SC or intranasal 60 minutes before bed. Add low-dose GHRP-6 50 mcg SC at the same time as DSIP for overnight GH pulse enhancement. Mood & Wellbeing Protocol: DSIP nightly + Semax 200 mcg intranasal each morning for sleep-restoration and BDNF-driven mood support. Perimenopause Sleep Protocol: DSIP 200 mcg + Kisspeptin-10 75 mcg SC twice weekly for combined sleep and HPG axis support.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
DSIP has a well-established safety profile with no significant adverse events documented at research doses. The most commonly reported effects are a pleasant drowsiness within 20–30 minutes of injection and, occasionally, vivid dreams — consistent with enhanced slow-wave and delta sleep activity. Morning grogginess is minimal compared to pharmaceutical sleep aids. No respiratory depression, dependency, withdrawal, or cognitive impairment has been documented — a significant advantage over benzodiazepines and Z-drugs. Mild injection site redness may occur.
Storage & Handling
Store lyophilized DSIP at 2–8°C, protected from light and moisture. Stable for up to 12–18 months in lyophilized form. Reconstitute with bacteriostatic water; a 5 mg vial with 2.5 mL BAC water yields 2,000 mcg/mL. Store reconstituted solution at 2–8°C and use within 28 days. DSIP is relatively stable compared to many neuropeptides but should still be protected from temperature extremes.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
